#United States #Robbins Geller #San Diego #Securities Fraud #Medpace Holdings

Robbins Geller Calls Medpace Holdings Investors to Action

In an important announcement for Medpace Holdings Inc. investors, Robbins Geller Rudman & Dowd LLP has revealed that those who purchased shares of Medpace (NASDAQ: MEDP) between April 22, 2025, and February 9, 2026, may have the opportunity to lead a class action lawsuit. Stakeholders who experienced substantial financial losses during this period are encouraged to consider acting as lead plaintiffs in this legal action.

The deadline for interested parties to take action is June 8, 2026. The class action lawsuit, titled Durbin v. Medpace Holdings Inc. (No. 26-cv-00346 in the Southern District of Ohio), accuses the company and several executives of breaching the Securities Exchange Act of 1934.

Allegations Against Medpace Holdings

Robbins Geller's complaint lays out significant allegations against Medpace, a clinical contract research organization (CRO) that provides outsourced clinical development services to various sectors, including biotechnology and pharmaceuticals. It is charged that during the class period, Medpace misled investors with false statements and failed to disclose crucial information related to its financial health.

Specifically, the lawsuit claims that Medpace consistently oversold its projected book-to-bill ratio for the fourth quarter of 2025. Furthermore, it highlights that the company was aware of the adverse impact cancellations had on its book-to-bill ratio yet chose not to disclose this information. Medpace maintained throughout the period that its projected book-to-bill ratio of 1.15 for Q4 2025 was both reasonable and achievable, despite warnings signs indicating a struggle within their business environment.

Moreover, the complaint alleges that Medpace management was not adequately concerned about the lack of diversity in its pre-backlog, suggesting a misleading level of confidence in its future prospects.

On February 9, 2026, when Medpace announced its fourth-quarter earnings, the company reported a disappointing book-to-bill ratio of 1.04, considerably lower than initially guided. This revelation caused Medpace’s stock price to plummet by nearly 16%, prompting concerns among investors regarding the company’s integrity.

How to Participate as a Lead Plaintiff

Investors who suffered losses during the specified class period can formally seek to be appointed as lead plaintiffs in the case. Under the Private Securities Litigation Reform Act of 1995, individuals with the greatest financial stake in the outcome and who represent a typical member of the proposed class may lead the lawsuit. As the lead plaintiff, one would take on a critical role in directing the litigation process and selecting legal representation.

It’s essential to note that participating as a lead plaintiff does not affect an investor’s right to share in any future recovery if the case succeeds. For those interested, details can be provided directly on Robbins Geller’s website or through contact with their attorneys, Ken Dolitsky or Michael Albert.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a prestigious law firm that specializes in securities fraud and shareholder rights litigation. In 2025, they ranked #1 on the ISS Securities Class Action Services Top 50 Report, having recovered over $916 million for investors. They are highly respected, boasting numerous successful recoveries in major securities cases, including the largest class action recovery in history concerning Enron Corp.

If you believe you qualify to lead this class action against Medpace Holdings, it's imperative to act before the upcoming deadline. Doing so could help address the alleged injustices faced by numerous investors while ensuring accountability for corporate misconduct.